Shares of BioTelemetry Inc. (NASDAQ:BEAT) hit a new 52-week high during trading on Tuesday . The company traded as high as $18.10 and last traded at $17.69, with a volume of 227,088 shares changing hands. The stock had previously closed at $17.50.

Separately, Zacks Investment Research cut shares of BioTelemetry from a “hold” rating to a “sell” rating in a research report on Tuesday, April 19th.

The stock has a 50-day moving average price of $16.46 and a 200-day moving average price of $13.17. The company has a market cap of $483.96 million and a P/E ratio of 43.92.

BioTelemetry (NASDAQ:BEAT) last issued its earnings results on Tuesday, April 26th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.10. The firm earned $48.60 million during the quarter, compared to the consensus estimate of $46.54 million. The company’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 EPS. Equities analysts forecast that BioTelemetry Inc. will post $0.71 earnings per share for the current fiscal year.

Other hedge funds and institutional investors have recently modified their holdings of the company. Royce & Associates LLC increased its position in shares of BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock valued at $7,086,000 after buying an additional 306,700 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of BioTelemetry by 8.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,317,266 shares of the company’s stock valued at $15,386,000 after buying an additional 98,737 shares in the last quarter. Russell Frank Co increased its position in shares of BioTelemetry by 58.9% in the fourth quarter. Russell Frank Co now owns 249,457 shares of the company’s stock valued at $2,933,000 after buying an additional 92,455 shares in the last quarter. 1492 Capital Management LLC increased its position in shares of BioTelemetry by 11.4% in the fourth quarter. 1492 Capital Management LLC now owns 321,761 shares of the company’s stock valued at $3,758,000 after buying an additional 32,932 shares in the last quarter. Finally, Gabelli Funds LLC purchased a new position in shares of BioTelemetry during the fourth quarter valued at about $1,190,000.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.